Heyiding Ceftazidime for Injection and 5% Glucose Injection

1. Indications and Usage
Severe Bacterial Infections:
Treatment of serious infections caused by susceptible microorganisms, including sepsis, bacteremia, and severe infections in immunocompromised patients (e.g., ICU, burn units).
Specific Site Infections:
Lower respiratory tract infections (including pneumonia), intra-abdominal and biliary tract infections, complicated urinary tract infections, and severe skin and soft tissue infections.
CNS Infections:
Meningitis (particularly caused by Haemophilus influenzae, Neisseria meningitidis, Pseudomonas aeruginosa, and Streptococcus pneumoniae).
2. Dosage and Administration
Route of Administration:
For Intravenous (IV) Infusion ONLY.
Recommended Dosage:
Adults: Typically 1 g to 2 g every 8 to 12 hours.
Severe Infections: Up to 3 g to 6 g per day divided into multiple doses.
Renal Impairment: Dosage must be adjusted based on creatinine clearance.
Critical Administration Instructions:
Mixing: Activate the double-chamber bag to mix the powder and the 5% Glucose Injection.
Compatibility: This formulation is specifically designed for 5% Glucose Injection and should not be mixed with other drugs.
3. Mechanism of Action
Cell Wall Inhibition:
Ceftazidime is a third-generation cephalosporin antibiotic that binds to penicillin-binding proteins (PBPs).
Bactericidal Effect:
It inhibits bacterial cell wall synthesis, exhibiting high activity against Gram-negative bacteria, including Pseudomonas aeruginosa, while being stable against many β-lactamases.
4. Safety and Warnings
Hypersensitivity:
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions. Contraindicated in patients with severe penicillin allergy.
Clostridioides difficile-Associated Diarrhea:
Broad-spectrum antibiotics may alter normal gut flora, leading to pseudomembranous colitis.
Renal and Hepatic Function:
Monitor renal and hepatic parameters, especially during prolonged therapy.
Neurotoxicity:
High doses in patients with renal impairment may cause seizures or encephalopathy.
5.Adverse Reactions and Clinical Research
Most Common Adverse Reactions:
Nausea, vomiting, diarrhea, injection site reactions (phlebitis), and skin rash.
Laboratory Abnormalities:
Transient elevation of liver enzymes, serum creatinine, and eosinophilia.
6.Drug Interactions
Aminoglycosides:
Potentially increased risk of nephrotoxicity if used concomitantly (must be administered separately).
Probenecid:
May increase and prolong ceftazidime serum concentrations.
Anticoagulants:
May enhance the anticoagulant effect of warfarin.
7.Pharmaceutical Information
Chemical Composition:
Powder Chamber: Contains Ceftazidime (as monohydrate) and Sodium Carbonate.
Liquid Chamber: Contains 5% Glucose Injection.
Appearance: White to off-white powder; colorless to slightly yellow liquid.
Packaging: Double-chamber bag (e.g., 1.0 g powder + 50 mL liquid).
Storage: Store at controlled room temperature.